Ozone-induced eosinophil recruitment to airways is altered by antigen sensitization and tumor necrosis factor- α blockade.

Publisher: published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society Country of Publication: United States NLM ID: 101607800 Publication Model: Print Cited Medium: Internet ISSN: 2051-817X (Electronic) Linking ISSN: 2051817X NLM ISO Abbreviation: Physiol Rep Subsets: MEDLINE

Original Publication: [Malden MA] : published by Wiley Periodicals, Inc. on behalf of the American Physiological Society and The Physiological Society, 2013-

Cell Movement*; Asthma/*immunology ; Eosinophils/*drug effects ; Ozone/*adverse effects ; Tumor Necrosis Factor-alpha/*metabolism; Animals ; Asthma/etiology ; Asthma/pathology ; Eosinophils/immunology ; Eosinophils/physiology ; Etanercept/pharmacology ; Female ; Guinea Pigs ; Immunosuppressive Agents/pharmacology ; Respiratory Mucosa/immunology ; Respiratory Mucosa/pathology ; Respiratory System/innervation ; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Ozone is an atmospheric pollutant that causes lung inflammation and airway hyperresponsiveness. Ozone's effects occur in two distinct phases that are mediated by different populations of eosinophils. In the acute phase 1 day after exposure, mature airway-resident eosinophils alter parasympathetic nerve function that results in airway hyperresponsiveness. At this time point, the severity of hyperresponsiveness correlates with the number of eosinophils in close proximity to airway nerves, but not with eosinophils in bronchoalveolar lavage. Three days later, newly divided eosinophils are recruited to airways by a tumor necrosis factor- α -dependent mechanism. These new eosinophils paradoxically attenuate ozone-induced airway hyperresponsiveness. Ozone's effects on airway tissue eosinophils and nerve-associated eosinophils 3 days after exposure are unknown. Thus, we tested ozone's effects on eosinophils in airway subepithelium and around airway nerves 1 and 3 days after ozone in nonsensitized and ovalbumin-sensitized guinea pigs with or without the tumor necrosis factor- α antagonist, etanercept, and compared changes in eosinophils with ozone-induced airway hyperresponsiveness. More eosinophils were present in small, noncartilaginous airways and along small airway nerves compared to large cartilaginous airways in all treatment groups. The number of airway and nerve-associated eosinophils were unaffected 1 day after ozone exposure, whereas significantly fewer airway eosinophils were present 3 days later. Airway and nerve-associated eosinophils were also decreased in small airways 3 days after ozone in sensitized animals. These changes were blocked by etanercept. Airway eosinophils, but not nerve-associated or bronchoalveolar lavage eosinophils correlated with airway hyperresponsiveness 3 days after ozone. Our findings indicate ozone causes persistent alterations in airway eosinophils and reinforce the importance of characterizing eosinophils' effects within distinct airway compartments.
(© 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society.)

Am J Physiol Lung Cell Mol Physiol. 2017 Jun 1;312(6):L969-L982. (PMID: 28258108)
J Appl Physiol (1985). 1994 Mar;76(3):1088-97. (PMID: 8005850)
Lung. 1994;172(3):169-81. (PMID: 8201831)
J Appl Physiol (1985). 1985 Dec;59(6):1879-85. (PMID: 4077795)
J Asthma. 2009 Oct;46(8):777-85. (PMID: 19863280)
PLoS One. 2013 Sep 18;8(9):e75351. (PMID: 24058677)
Environ Health Perspect. 2010 Sep;118(9):1189-95. (PMID: 20382579)
Am J Physiol Lung Cell Mol Physiol. 2013 Apr 15;304(8):L519-29. (PMID: 23377347)
J Physiol. 1995 Jul 1;486 ( Pt 1):257-65. (PMID: 7562641)
Am Rev Respir Dis. 1979 Nov;120(5):1059-67. (PMID: 507522)
Respir Med. 2005 Sep;99(9):1175-82. (PMID: 16085220)
PLoS One. 2010 May 10;5(5):e10562. (PMID: 20479945)
Br J Pharmacol. 1990 Feb;99(2):293-6. (PMID: 2158372)
Br J Pharmacol. 2009 Jan;156(1):201-10. (PMID: 19134001)
J Appl Physiol (1985). 1999 Oct;87(4):1272-8. (PMID: 10517752)
J Allergy Clin Immunol. 2016 Feb;137(2):571-8. (PMID: 26282284)
N Engl J Med. 2006 Feb 16;354(7):697-708. (PMID: 16481637)
Am J Respir Cell Mol Biol. 2014 Aug;51(2):251-61. (PMID: 24605871)
Am J Physiol. 1999 May;276(5):L709-14. (PMID: 10330026)
PLoS One. 2012;7(9):e44780. (PMID: 23049757)
J Allergy Clin Immunol. 2008 Jan;121(1):5-10; quiz 11-2. (PMID: 18036647)
Br J Pharmacol. 1984 Dec;83(4):973-8. (PMID: 6518347)
Environ Health. 2015 Mar 18;14:25. (PMID: 25889205)
J Appl Physiol Respir Environ Exerc Physiol. 1984 Dec;57(6):1783-9. (PMID: 6392228)
J Allergy Clin Immunol. 1997 Dec;100(6 Pt 1):802-8. (PMID: 9438490)
Proc West Pharmacol Soc. 1996;39:57-60. (PMID: 8895970)
J Appl Physiol (1985). 1992 Mar;72(3):1016-23. (PMID: 1568955)
Am J Physiol Lung Cell Mol Physiol. 2011 Feb;300(2):L176-84. (PMID: 21056958)
Free Radic Biol Med. 2001 Dec 1;31(11):1442-7. (PMID: 11728816)
J Allergy Clin Immunol. 2007 Jun;119(6):1415-22. (PMID: 17418379)
Ann Med. 2000 Oct;32(7):429-39. (PMID: 11087162)
Respir Res. 2010 Jan 19;11:5. (PMID: 20085630)
Environ Health Perspect. 2008 Mar;116(3):381-8. (PMID: 18335107)
Blood. 2002 Mar 15;99(6):2214-20. (PMID: 11877300)
J Allergy Clin Immunol. 2012 Jan;129(1):259-61.e1-2. (PMID: 22196529)
J Allergy Clin Immunol. 2016 Feb;137(2):390-9. (PMID: 26187234)
J Clin Invest. 1993 Apr;91(4):1314-8. (PMID: 8473484)
Am J Respir Crit Care Med. 2003 Jan 15;167(2):199-204. (PMID: 12406833)
Physiol Rep. 2017 Dec;5(24):. (PMID: 29242307)
Am J Respir Crit Care Med. 1995 May;151(5):1336-45. (PMID: 7735583)
J Smooth Muscle Res. 2005 Jun;41(3):153-61. (PMID: 16006748)
Clin Exp Allergy. 2014 Sep;44(9):1119-36. (PMID: 24961290)
Am J Physiol Lung Cell Mol Physiol. 2005 Oct;289(4):L627-35. (PMID: 15923207)
Am J Respir Cell Mol Biol. 2014 Oct;51(4):494-501. (PMID: 24735073)
Am J Respir Crit Care Med. 2009 Apr 1;179(7):549-58. (PMID: 19136369)
Allergy Asthma Immunol Res. 2015 Jul;7(4):339-45. (PMID: 25749776)
J Physiol. 1999 Aug 1;518 ( Pt 3):843-55. (PMID: 10420019)
Am J Physiol. 1997 Apr;272(4 Pt 1):L731-8. (PMID: 9142948)
J Exp Med. 1999 Nov 15;190(10):1465-78. (PMID: 10562321)
Am J Physiol Lung Cell Mol Physiol. 2002 Jun;282(6):L1279-88. (PMID: 12003784)
J Environ Pathol Toxicol Oncol. 1999;18(4):323-34. (PMID: 15281245)
Respiration. 2012;83(6):529-42. (PMID: 22507883)
J Allergy Clin Immunol. 2010 Sep;126(3):537-44.e1. (PMID: 20816188)
Br J Pharmacol. 1997 Sep;122(1):133-41. (PMID: 9298539)
Clin Exp Allergy. 2010 Apr;40(4):563-75. (PMID: 20447076)
Am Rev Respir Dis. 1985 Mar;131(3):314-20. (PMID: 3977170)
Am J Respir Crit Care Med. 2011 May 1;183(9):1215-21. (PMID: 21216881)
Am J Respir Cell Mol Biol. 2008 Dec;39(6):730-8. (PMID: 18617681)
J Pharmacol Exp Ther. 2017 Apr;361(1):172-180. (PMID: 28138042)
Am J Physiol. 1997 Jul;273(1 Pt 1):L93-103. (PMID: 9252545)
Ann Allergy Asthma Immunol. 2009 Dec;103(6):474-9. (PMID: 20084840)
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2013;34(1):131-41. (PMID: 23917748)
Am J Respir Cell Mol Biol. 2014 Jul;51(1):43-55. (PMID: 24471696)
Ann Allergy Asthma Immunol. 2014 Feb;112(2):108-15. (PMID: 24468249)
Am J Respir Crit Care Med. 2002 Oct 15;166(8):1073-7. (PMID: 12379550)
N Engl J Med. 2009 Mar 5;360(10):973-84. (PMID: 19264686)
Am Rev Respir Dis. 1978 Aug;118(2):287-94. (PMID: 697179)
Thorax. 1999 Mar;54(3):268-72. (PMID: 10325905)
J Immunol. 1992 Nov 15;149(10):3309-15. (PMID: 1385521)
J Clin Invest. 2006 Jan;116(1):228-36. (PMID: 16374515)
Am Rev Respir Dis. 1985 Mar;131(3):312-3. (PMID: 3977169)
Environ Res. 2014 Jul;132:421-9. (PMID: 24858282)
Am Rev Respir Dis. 1993 Nov;148(5):1363-72. (PMID: 8239177)
Am J Respir Crit Care Med. 2001 May;163(6):1484-92. (PMID: 11371422)
Annu Rev Med. 1984;35:451-67. (PMID: 6144287)
J Appl Physiol (1985). 1994 Sep;77(3):1492-9. (PMID: 7836157)
J Allergy Clin Immunol. 2001 Jun;107(6):945-57. (PMID: 11398070)
Thorax. 2016 Dec;71(12):1097-1109. (PMID: 27343213)
J Appl Physiol Respir Environ Exerc Physiol. 1984 Oct;57(4):1034-8. (PMID: 6438025)
J Allergy Clin Immunol. 2014 Aug;134(2):350-9. (PMID: 24522093)

K08 HL121254 United States HL NHLBI NIH HHS; T32 HL083808 United States HL NHLBI NIH HHS; TL1 TR000129 United States TR NCATS NIH HHS

Keywords: TNF α; Airway; asthma; eosinophil; nerve; ozone

0 (Immunosuppressive Agents)
0 (Tumor Necrosis Factor-alpha)
66H7ZZK23N (Ozone)
OP401G7OJC (Etanercept)

Date Created: 20171216 Date Completed: 20180718 Latest Revision: 20230812

20231215

PMC5742702

10.14814/phy2.13538

29242307